Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
BloombergDuration: 1:52
Read the full storyUp next
- BlackRock's Rieder Says Front End of Yield Curve 'Still Very Attractive'
- JPMorgan's Gehl on Tech & AI Fundraising, Capex, IPO
- Europe 'Not Well Prepared for Winter' on Energy, Goldman's Della Vigna Says
- Oil Climbs as Trump Reportedly Weighs Iran Strikes Ahead of Midterms
- Yardeni Sees Bond Yields Heading in 'Danger Zone' Direction
- Fed's Waller Sees Some Flexibility on Rate-Hike Timing
